Also known as Tα1 · Thymalfasin · Zadaxin
Thymus-derived 28-amino-acid peptide approved in many countries as an immunomodulator.
Thymosin α1 is a 28-amino-acid peptide originally isolated from thymic tissue. Approved in numerous countries as adjunctive therapy in chronic hepatitis B / C and as an immune-system modulator.
Thymosin alpha-1 (Tα1, thymalfasin) is a 28-amino-acid peptide originally isolated from the thymus, the organ where T cells mature. It acts as an immune modulator, helping to restore and direct T-cell responses.
Unlike most catalogued peptides, Tα1 is approved in many countries (marketed as Zadaxin) as an adjunct in chronic hepatitis B and C and in other immune contexts, though it is not FDA-approved in the United States. It is among the most clinically studied immunomodulatory peptides.
TLR9-mediated DC activation; Th1 immune polarization.
Behind every vial of Thymosin Alpha-1 is the same exacting pipeline every research peptide runs — but the chemistry plays out differently for this molecule. Here is how Thymosin Alpha-1, specifically, is brought into being.
On paper, Thymosin Alpha-1 is C129H215N33O55 — about 3,108.3 daltons of precisely arranged atoms. Before a single bond is made, the target sequence, salt form, and purity threshold are written down as the contract the finished material must meet.
Assembling Thymosin Alpha-1 means roughly 28 coupling cycles on the synthesizer — one protected residue added at a time, which is also 28 chances for an incomplete coupling to seed a deletion impurity.
The crude mixture — Thymosin Alpha-1 plus its deletions and side products — is then separated on preparative HPLC, and where the cut is taken decides the difference between a genuinely pure peptide and a barely-passable one.
A real batch of Thymosin Alpha-1 proves itself: identity confirmed by mass spectrometry against its ~3,108.3 Da, purity read directly off an analytical HPLC trace, water and counterion content measured. That batch-specific certificate of analysis is the only honest way to know what is actually in a vial of Thymosin Alpha-1 — and a short, cold, accountable chain of custody is how that purity survives the trip to your bench.
Producing Thymosin Alpha-1 to a genuine purity spec means solid-phase synthesis, preparative HPLC purification, and batch quality control — none of it cheap, and none of it something you can verify by eye.
Don't judge a vial by its cake. A fluffy, good-looking lyophilized powder reflects bulking agents and freeze-drying parameters — not purity. Insist on a batch-specific certificate of analysis.
Recent clinical trials and publications mentioning Thymosin Alpha-1, pulled automatically from ClinicalTrials.gov and PubMed and refreshed daily. Listings are unfiltered search results, not curated endorsements.
Thymosin alpha-1 is a thymus-derived immunomodulatory peptide (Zadaxin) used in many countries as an adjunct in chronic hepatitis and other immune conditions.
It supports and directs T-cell responses, in part through TLR9-mediated dendritic-cell activation and a shift toward Th1 immunity.
It is approved in numerous countries but not by the US FDA. This page is a research and educational reference.
Chronic viral hepatitis, and as an immune-supporting adjunct in sepsis and oncology research.
Dosing protocols, mechanism, comparisons, and the latest trials — citation-backed answers grounded in PubMed, PubChem, and ClinicalTrials.gov.